| Date | Title | Description |
| 08.04.2026 | Arcadia Expands Leadership Team to Redefine AI-Driven Healthcare Performance and Scale into Life Sciences | Arcadia (arcadia.io), the outcomes company enabling leading healthcare organizations to transform care and cost outcomes, announced the appointment of three executives to its leadership team: Chris Rallo as Chief Product Officer, Sandy Leon... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 04.04.2026 | Syneron Bio Fuels Innovation with $150M Investment | Syneron Bio secured $150 million in Series B financing. This major investment drives its intelligent Synova platform. The capital fuels advanced macrocyclic peptide drug discovery. It targets critical unmet needs across oncology, autoimmune... |
| 03.04.2026 | Syneron Bio Closes $150M Series B Financing | Syneron Bio, a Beijing, China-based intelligent platform-driven macrocyclic peptide drug discovery company, closed a $150m Series B financing round.
The round was led by an international life-science fund, with co-lead participation from De... |
| 03.04.2026 | Syneron Bio: $150 Million Raised For Macrocyclic Peptide Drug Discovery Platform And Pipeline Advancement | Syneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development... |
| 03.04.2026 | Syneron Bio Announces Completion of $150 Million Series B Financing | BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international ... |
| 03.04.2026 | Declining patent filings show Britain has stopped innovating | There are lots of ways to measure innovation, but if we go by patent filings, it’s a sorry image for the UK, writes Ayushma Maharjan
Britain’s days as the home of the Industrial Revolution are long gone. But many people still cling to the n... |
| 02.04.2026 | Imfinzi+Imjudo improves PFS in early liver cancer | Imfinzi+Imjudo improves PFS in early liver cancer
Thu, Apr 02, 2026 08:21 CET Report this content
2 April 2026
Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvem... |
| 01.04.2026 | Total Voting Rights and Admission of Shares | Total Voting Rights and Admission of Shares
Wed, Apr 01, 2026 16:00 CET Report this content
1 April 2026
Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
Total Voting Rights
The following notif... |
| 31.03.2026 | Efzimfotase alfa Ph3 program show positive results | Efzimfotase alfa Ph3 program show positive results
Tue, Mar 31, 2026 08:00 CET Report this content
This announcement contains inside information
31 March 2026
Efzimfotase alfa demonstrated positive results from global Phase III clinical pro... |
| 31.03.2026 | Honda Office Launches "PR Collective Asia" to Advise Japanese Enterprises on Strengthening Corporate and Brand Reputation | The Collective is a regional network of senior communications strategists across six Southeast Asian markets to guide Japanese companies in building trusted and respected corporate and brand presence overseas
TOKYO and SINGAPORE, March 31, ... |
| 31.03.2026 | Building Europe’s deeptech backbone: Inside European Deeptech Week 2026 | From March 16 to 20, Paris became the command centre for the future of European deeptech, bringing together founders, industrialists, investors, and public decision-makers at Bpifrance's headquarters to accelerate the transition from scienc... |
| 31.03.2026 | Amani Therapeutics: $25 Million Raised To Advance Neuropsychiatric Therapy AM-01 | Amani Therapeutics has raised $25 million in a Series A financing to advance its lead program, AM-01, a potential best-in-class therapy targeting serious neuropsychiatric disorders.
The newly formed biotechnology company, backed by RTW Inve... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 27.03.2026 | European stocks close lower as Trump extends Iran strike hiatus and G7 ministers meet | The sell-off in European stocks continued on Friday after U.S. President Donald Trump extended the ongoing hiatus of attacks on Iran’s energy infrastructure.
The pan-European Stoxx 600 provisionally ended the session 0.9% lower with nearly ... |
| 27.03.2026 | AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed | Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former s... |
| 27.03.2026 | Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more | - |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 27.03.2026 | Tozorakimab met OBERON/TITANIA primary endpoints | Tozorakimab met OBERON/TITANIA primary endpoints
Fri, Mar 27, 2026 08:14 CET Report this content
This announcement contains inside information
27 March 2026
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in pat... |
| 26.03.2026 | Keymed Biosciences Announces 2025 Annual Results and Business Updates | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.
Revenue Leaps... |
| 24.03.2026 | Amani Therapeutics Raises $25M in Series A Funding | Amani Therapeutics, a NYC-based biotechnology company developing treatments for serious neuropsychiatric disorders, raised $25M in Series A funding.
Backers were not disclosed.
The company intends to use the funds to expand operations and R... |
| 20.03.2026 | Notification of Admission of Shares | Notification of Admission of Shares
Fri, Mar 20, 2026 12:00 CET Report this content
20 March 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
AstraZeneca PLC (the Company) announced today the following informatio... |
| 19.03.2026 | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody thera... |
| 18.03.2026 | Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy | TAIPEI and SAN DIEGO, March 18, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announce... |
| 18.03.2026 | Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer | SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, inves... |
| 16.03.2026 | Companies House Suspends Online Filings After Data Glitch | The UK’s official corporate register has suspended its online filing service after a website glitch exposed sensitive personal data and raised concerns that company records could be altered by unauthorised users.
Companies House confirmed i... |
| 16.03.2026 | Imfinzi approved in EU for early gastric cancer | Imfinzi approved in EU for early gastric cancer
Mon, Mar 16, 2026 08:00 CET Report this content
16 March 2026
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal canc... |
| 14.03.2026 | Corporate Democracy in Action: Shareholder Meetings Shape Future | Annual General Meetings are vital corporate events. Shareholders actively shape company direction. They vote on critical matters. These include electing directors, appointing auditors, and approving executive remuneration. Key financial dec... |
| 13.03.2026 | Waiv Secures $33 Million to Revolutionize Cancer Diagnostics with AI | Waiv, an AI precision testing innovator, recently secured $33 million in funding. This Paris-based company spun out from Owkin. It transforms cancer diagnostics. Waiv's powerful AI analyzes digital histopathology and multimodal clinical dat... |
| 13.03.2026 | Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics | Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datas... |
| 13.03.2026 | European Businesses Send Warning Over US Cloud Reliance | European businesses are increasingly raising concerns that the continent’s push for tech sovereignty could hit profits and undermine competitiveness, as many seek to reduce reliance on US technology giants.
Companies across sectors from ban... |
| 12.03.2026 | Abivax denies French media report of AstraZeneca takeover | Abivax shares soared on Thursday after a French media report that AstraZeneca was in talks to acquire it.
But a company spokesperson denied the report to CNBC.
Abivax has been the subject of intense takeover speculation for months.
French b... |
| 12.03.2026 | Waiv: $33 Million Raised For AI Precision Oncology Testing Platform | Waiv, a Paris-based developer of AI-powered precision oncology testing technology, announced it has raised $33 million in financing to accelerate global deployment of its AI precision testing platform and expand its clinical-grade diagnosti... |
| 10.03.2026 | Hormuz Strait Crisis: Escalating Threat to Global Tech, Pharma, and Economic Stability | Middle East tensions threaten global supply chains. The Strait of Hormuz, a critical maritime choke point, fuels economic instability. Disruptions risk soaring prices for electronics, pharmaceuticals, and essential goods. The AI economy, de... |
| 10.03.2026 | Notice of AGM | Notice of AGM
Tue, Mar 10, 2026 12:00 CET Report this content
10 March 2026
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2026 and Shareholders' Circul... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 07.03.2026 | The 15th Five-Year Plan featuring opening up: China and the world sharing the future | BEIJING, March 7, 2026 /PRNewswire/ -- A news report from China.org.cn on China's new efforts on further opening up:
 
The 15th Five-Year Plan featuring opening up: China and the world sharing the future
The yea... |
| 06.03.2026 | Orexo changes the organizational structure and management team to increase focus on development of new products | Orexo changes the organizational structure and management team to increase focus on development of new products
Fri, Mar 06, 2026 15:30 CET Report this content
Uppsala, Sweden – March 6, 2026 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), tod... |
| 06.03.2026 | Director/PDMR Shareholding | Director/PDMR Shareholding
Fri, Mar 06, 2026 12:10 CET Report this content
6 March 2026
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 5 March 2026, an award of the Company's o... |
| 04.03.2026 | Supply chain disruptions from the Iran war could raise prices for drugs, electronics and more | Please subscribe to IBJ to decode this article.
/>hsdiemuapnoe ptc oesrisE/samin updf-bum:cfetijsuta srr,zajrt,nadid yhmemirwi l=cMSeohmegsHec ism cruh eeiahlck counpyiol-iweraua _ipp hTs&cali-a it ia heaupwpends iatay r adytrkl g ad... |
| 02.03.2026 | Gothenburg leads the way in medical simulation | Gothenburg leads the way in medical simulation
Mon, Mar 02, 2026 08:01 CET Report this content
Thanks to advanced simulation technology, doctors can improve their surgical skills more quickly and safely. The technique benefits both patients... |
| 28.02.2026 | Novo Nordisk Faces Setback as Key Weight Loss Drug Falls Short | Novo Nordisk experienced a significant blow. Its experimental weight-loss medication, CagriSema, failed to meet expectations in a crucial clinical trial. The drug did not demonstrate non-inferiority against Eli Lilly's rival product, tirzep... |
| 27.02.2026 | AI Drug Discovery: Turbine Secures $25M to Revolutionize Biopharma with Virtual Biology | Turbine, the innovative virtual biology company based in Budapest, just secured $25 million in Series B funding. This significant capital infusion, spearheaded by Interactive Venture Partners and backed by Beiersdorf Venture Capital, accele... |
| 27.02.2026 | AstraZeneca Unveils 2025 Financials, Bolstering Global Investor Confidence | AstraZeneca solidified its 2025 financial transparency. The global biopharma leader published its comprehensive Annual Report. It simultaneously filed the critical Form 20-F with both UK and US regulatory bodies. This dual action ensures br... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 27.02.2026 | There’s a ‘bearish-to-bullish’ reversal happening in this mid-cap biotech stock, says Carter Worth | - |
| 27.02.2026 | A booming employee benefit at the heart of America’s affordability debate | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
An employee benefit known as earned wage access has become even more popular than 401(k) plan participation at some companies.
Early access to pay is offered by many of th... |
| 26.02.2026 | AstraZeneca prices a $2bn bond offering | AstraZeneca prices a $2bn bond offering
Thu, Feb 26, 2026 08:00 CET Report this content
26 February 2026
AstraZeneca prices a $2bn bond offering
AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZenec... |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 25.02.2026 | CNBC’s UK Exchange newsletter: With shares up 1,200%, Rolls-Royce’s CEO has lots to shout about | This week, we look ahead to full-year results from Rolls-Royce, one of Britain’s most prestigious companies.
It has emerged from a torrid time around the pandemic to become one of the best-performing stocks in the FTSE 100 in recent times.
... |
| 25.02.2026 | Dutch engineering company joins Gothenburg’s health innovation cluster | Dutch engineering company joins Gothenburg’s health innovation cluster
Wed, Feb 25, 2026 17:23 CET Report this content
A little over a year ago, Gothenburg’s life science sector caught the eye of Dutch engineering company Demcon life scienc... |
| 25.02.2026 | Filing of Form 20-F with SEC | Filing of Form 20-F with SEC
Wed, Feb 25, 2026 08:00 CET Report this content
25 February 2026
Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission
AstraZeneca PLC (the Company) announced today that, on 24 Febr... |
| 24.02.2026 | Turbine Raises $25M in Series B Funding | Turbine, a Budapest, Hungary-based virtual biology company, raised $25M in Series B funding.
The round was led by Interactive Venture Partners with participation from Beiersdorf Venture Capital.
The company intends to use the funds to expan... |
| 24.02.2026 | Annual Financial Report | Annual Financial Report
Tue, Feb 24, 2026 12:00 CET Report this content
24 February 2026
Annual Financial Report
AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2025 (the Annual R... |
| 24.02.2026 | Directorate change | Directorate change
Tue, Feb 24, 2026 08:00 CET Report this content
24 February 2026
Non-Executive Board Changes
AstraZeneca PLC announced today that Non-Executive Director Nazneen Rahman will retire from the Board having joined in 2017. Thi... |
| 24.02.2026 | Turbine: $25 Million Series B Raised For Virtual Biology Platform And Immunology Expansion | Turbine, a virtual biology company focused on AI-powered drug discovery, announced it has raised $25 million in a Series B financing round led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors inc... |
| 23.02.2026 | Wihlborgs acquires property of 10 300 sqm in Carlsberg District | Wihlborgs acquires property of 10 300 sqm in Carlsberg District
Mon, Feb 23, 2026 12:00 CET Report this content
Wihlborgs has signed an agreement to acquire all commercial parts in the project Caroline Hus in Carlsberg District in Copenhage... |
| 23.02.2026 | Novo Nordisk shares tumble after drug trial falls short | Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff.
The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 25... |
| 20.02.2026 | Fixed-duration Calquence combo approved in US | Fixed-duration Calquence combo approved in US
Fri, Feb 20, 2026 08:00 CET Report this content
20 February 2026
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic ... |
| 20.02.2026 | Lantmännen ranks as one of Sweden’s most meaningful companies—for the fourth year in a row | Lantmännen ranks as one of Sweden’s most meaningful companies—for the fourth year in a row
Fri, Feb 20, 2026 12:30 CET Report this content
In Sweden, the 50 largest companies are listed and ranked for the title of Sweden’s most meaningful c... |
| 19.02.2026 | Американская фармкомпания Johnson & Johnson инвестирует $1 млрд в завод клеточной терапии в США | J&J инвестирует $1 млрд в новый завод в Пенсильвании на фоне курса США на развитие производства. Johnson & Johnson сообщила в среду, что вложит более $1 млрд в строительство нового предприятия по производству клеточной терапии в шта... |
| 18.02.2026 | Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss | The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said.
Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and W... |
| 17.02.2026 | Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer | Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Tue, Feb 17, 2026 08:00 CET Report this content
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 11.02.2026 | CNBC’s UK Exchange newsletter: Compass shifts its trading to dollars — and it might not be the last | A recent change to the rules governing how companies may be admitted to indices, like the FTSE 100, run by FTSE Russell means those whose shares change hands in dollars and euros may now enter these indices.
It has prompted a couple of Foot... |
| 10.02.2026 | CNBC Daily Open: U.S. markets rise on tech rebound, while ‘Takaichi trade’ lifts Japanese stocks | “Impossible” to move 40% of chip supply chain from Taiwan to the U.S., the island says.
China lashes out at the U.K.’s expansion of a visa scheme for Hong Kong residents.
U.S. urges ships to stay ‘as far as possible’ away from Iranian water... |
| 10.02.2026 | Final Results | Final Results
Tue, Feb 10, 2026 08:00 CET Report this content
10 February 2026
AstraZeneca results: FY and Q4 2025
Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period
Revenue and EPS summary
FY... |
| 08.02.2026 | AstraZeneca Makes Historic NYSE Debut, Targets $80 Billion Future | AstraZeneca launched ordinary share trading on the New York Stock Exchange February 2, 2026. This historic event signifies the largest company transfer by market capitalization in NYSE history. The strategic shift provides significantly bro... |
| 08.02.2026 | AstraZeneca's Historic NYSE Move Reshapes Global Biopharma Landscape | AstraZeneca completed a landmark transfer to the New York Stock Exchange. Its ordinary shares now trade there, a historic move. It represents the largest company transfer by market capitalization in NYSE history. This strategic shift harmon... |
| 08.02.2026 | Global week ahead: Tech rotation puts European stocks back in play | Stoxx 600 holds near record highs despite AI-led tech rout
UniCredit and Commerzbank lead bank earnings in Europe this week
Medical groups Philips and AstraZeneca also set to release earnings
L’Oreal sales in focus amid recovery in U.S. and... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 05.02.2026 | AstraZeneca Seeks Green Light to Sell New Lupus Drug Anifrolumab in China | (Yicai) Feb. 5 -- AstraZeneca’s application to bring its new lupus drug anifrolumab, which treats adult Asian patients with the autoimmune disease systemic lupus erythematosus, to the Chinese market is currently under review, the UK pharmac... |
| 05.02.2026 | Intervacc announces change of CEO | Intervacc announces change of CEO
Thu, Feb 05, 2026 19:15 CET Report this content
The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.
S... |
| 05.02.2026 | TrumpRx.gov Launches with 80% Discounts on Ozempic and Wegovy | What You Should Know
The Launch: President Trump has officially launched TrumpRx.gov, a consumer-facing digital portal that allows patients to access “Most-Favored-Nation” (MFN) pricing on high-cost drugs. The initial rollout features deals... |
| 04.02.2026 | Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therape... |
| 03.02.2026 | Rolls-Royce: FTSE 100 giants shares eye all-time high in tariff comeback | Shares in aerospace giant Rolls-Royce were back on the march to an all-time high after a tariff salvo from the US sent the City giant’s stock tumbling.
The FTSE 100 titan’s stock was up 1.6 per cent to 1,250.50p on Tuesday morning, making i... |
| 03.02.2026 | NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer | NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Ashley Mastr... |
| 03.02.2026 | Wellspect HealthCare joins the National Climate Initiative within the Healthcare and Life Science Sector in Sweden | Wellspect HealthCare joins the National Climate Initiative within the Healthcare and Life Science Sector in Sweden
Tue, Feb 03, 2026 17:25 CET Report this content
Mölndal, Sweden – February 3, 2026 – A broad public–private partnership is no... |
| 03.02.2026 | Biorce: $52.5 Million Series A Raised To Expand Globally And Apply AI to Clinical Trial Design | Biorce, a Barcelona-based health AI company focused on using artificial intelligence to improve how clinical trials are designed and executed, announced it has closed a $52.5 million Series A round to accelerate international expansion and ... |
| 03.02.2026 | Update on Saphnelo subcutaneous administration | Update on Saphnelo subcutaneous administration
Tue, Feb 03, 2026 08:16 CET Report this content
3 February 2026
Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus
The US Food and Drug Admin... |
| 02.02.2026 | CNBC Daily Open: Markets see Warsh as a safe pick for Fed chair — causing gold and silver to plunge | Warsh was at the Fed from 2006 to 2011, but emerged a critic of it.
“Confident” government shutdown will end by Tuesday: U.S. Speaker Johnson.
AstraZeneca lists in New York days after it announced billions in investment in China.
Major U.S.... |
| 02.02.2026 | From PopMart to JD.com: Britain and China rush to forge business deals as diplomatic thaw takes hold | U.K’s prime minister met with the Chinese president and secured deals that would see hundreds of millions worth of new investments from Chinese businesses.
Beijing promised to expand market access for British companies and improve a busines... |
| 02.02.2026 | Employment falls despite manufacturing output hitting new high | Employment across the manufacturing sector dropped despite output jumping to its highest level in 17 months, new data has shown.
Manufacturers continued shedding staff due to high pay and tax pressures, according to S&P Global’s latest ... |
| 02.02.2026 | Imfinzi recommended in EU for early gastric cancer | Imfinzi recommended in EU for early gastric cancer
Mon, Feb 02, 2026 08:05 CET Report this content
02 February 2026
Imfinzi perioperative regimen recommended for approval in the EU by
CHMP for patients with early gastric and gastroesophagea... |
| 02.02.2026 | AstraZeneca begins trading on NYSE | AstraZeneca begins trading on NYSE
Mon, Feb 02, 2026 08:00 CET Report this content
02 February 2026
AstraZeneca begins trading on the New York Stock Exchange
Ordinary shares now trade across the NYSE, LSE and STO under a harmonised global l... |
| 02.02.2026 | NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer | NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Kristen Scho... |
| 02.02.2026 | FTSE 100 hits fresh record after gold and silver rout | The FTSE 100 hit a fresh record on Monday despite being swept up in a global sell-off of metals and tech stocks that had pushed Asian and European stock markets deep into the red earlier in the day.
The UK’s blue-chip index closed up 118 po... |
| 01.02.2026 | AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation | AstraZeneca has announced it’s investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs.
The developments come at a critical time for the pharma industry as companies are increasingly lo... |
| 01.02.2026 | Llamas are big pharma’s secret weapon to find new drugs | Getting your Trinity Audio player ready...
By Lisa Pham, Bloomberg News
One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears flattened defiantly. A third rushes to gree... |
| 31.01.2026 | Europe's Banking Colossus: HSBC Hits $300 Billion Milestone | HSBC achieved a historic $300 billion market capitalization. It is the first European bank to reach this monumental milestone. Shares soared. An all-time high was set. Surging wealth management fees and an upgraded target price fueled the a... |
| 31.01.2026 | Britain's China Strategy: Billions Invested, Relations Realigned | UK Prime Minister Keir Starmer concluded a pivotal visit to China. He pursued stronger economic ties. AstraZeneca announced a $15 billion investment in Chinese pharmaceuticals. A visa-free travel deal was secured for UK citizens visiting Ch... |
| 31.01.2026 | Britain's Starmer ends China trip aimed at reset despite Trump warning | SHANGHAI: British Prime Minister Keir Starmer wrapped up a four-day trip to China on Saturday (Jan 31), after his bid to forge closer ties prompted warnings from United States President Donald Trump.
Starmer's visit was the first to China b... |
| 31.01.2026 | Starmer looks to woo Japanese investors amid Asia trip backlash | Keir Starmer said he would hold discussions with investors and business owners in Japan after landing in Tokyo, with the Prime Minister hoping to defy critics of his recent trip to China with new deals to boost the UK economy.
Speaking on a... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 30.01.2026 | World leaders flock to Beijing, hedging against U.S. disruptions | At least five world leaders have visited Beijing in January alone.
The high-level visits come as countries navigate tense U.S. relations.
Business executives are also using the opportunity for China deals.
BEIJING — Countries that shunned C... |
| 30.01.2026 | Is Starmer’s China visit a lose-lose trip? | Starmer was looking for win-win, Golden Era opportunities from his China visit, but the reality has yielded few tangible outcomes, writes Sam Goodman
Keir Starmer’s visit to Beijing this week has been a carefully stage-managed affair with b... |
| 30.01.2026 | AstraZeneca to Invest USD15 Billion in China by 2030 to Expand Drug Production, R&D | (Yicai) Jan. 30 -- UK-Swedish drugmaker AstraZeneca plans to invest USD15 billion in China over the next five years to expand its drug manufacturing, research, and development footprint in the country.
The investment will cover the entire v... |
| 30.01.2026 | Britain's Starmer hails 'good progress' after meeting China's Xi | BEIJING: Britain's Prime Minister Keir Starmer hailed "really good progress" on issues including visa-free travel and tariffs during talks with Chinese leader Xi Jinping in Beijing on Thursday (Jan 29).
Starmer's visit to China is... |
| 30.01.2026 | ‘Very dangerous’: Trump reportedly warns UK of doing business with China as Starmer seeks a reset | Trump warned the U.K. that it would be “very dangerous” for the country to do business with China.
China to allow visa-free travel for U.K. citizens, lower whisky tariffs by half.
AstraZeneca to invest $15 billion in China through 2030.
Sta... |
